Exact presentation first
“Zepbound pen” can mean two different devices
The Eli Lilly Zepbound label updated April 22, 2026 includes a prefilled single-dose pen and a single-patient-use KwikPen that contains four fixed weekly doses. It also includes single-dose and multi-dose vials. The single-dose pen uses a lock ring, purple injection button, clicks, and a gray-plunger completion check. The KwikPen uses a compatible new pen needle, priming, a dose knob, and a dose-window checkpoint. Advice for one device should not be transferred to the other.
- Read the carton and pharmacy label and match the device to the Instructions for Use supplied with that exact package.
- Do not interpret a KwikPen dose window with the single-dose pen’s gray-plunger rule or use KwikPen troubleshooting on a single-dose pen.
- A Zepbound vial, Mounjaro device, or compounded tirzepatide prescription has a different identity and requires its own instructions.
Single-dose pen checkpoint
Use the gray plunger—not click counting—to check the single-dose pen
For the current Zepbound single-dose pen, the Instructions for Use say to press and hold the purple injection button for up to 10 seconds. The first click means the injection started, and the second click means it completed. Some people may hear a softer click before the second loud click. The instructions identify a visible gray plunger as the completion check. If the gray plunger is not visible, they direct the patient to contact Lilly for further instructions and store the pen safely to avoid an accidental needle stick.
- Do not decide that the dose failed only because the sound differed from a prior injection; inspect the official gray-plunger checkpoint.
- If the gray plunger is not visible, do not press the device again, dismantle it, or repeat the dose while waiting for instructions.
- A drop of liquid at the needle tip before injection or a small drop of liquid or blood on the skin afterward is addressed in the instructions and does not by itself measure how much medicine entered.
KwikPen checkpoint
A KwikPen problem follows its dose-window and needle-specific instructions
The Zepbound KwikPen contains four fixed doses and requires a new compatible pen needle for each injection. Its Instructions for Use include priming before each weekly injection and a dose-window checkpoint before the needle is removed. They say not to count clicks when selecting the dose. If the full-dose checkpoint is not shown, the instructions describe a presentation-specific completion step without redialing. If the patient still thinks the full dose was not received, they say not to start over or repeat the injection and to use the troubleshooting and support pathway.
- A blocked needle, hard-to-push dose knob, or inability to dial the full fixed dose has specific KwikPen troubleshooting; do not substitute a social-media click chart.
- Do not inject leftover medicine after four doses or when the pen cannot dial a full dose, and do not transfer medicine from the KwikPen into a syringe.
- Never improvise priming or needle replacement after an uncertain injection; contact Lilly, the pharmacist, or the prescriber when the supplied instructions do not resolve the problem.
Dose uncertainty
An uncertain injection is not automatically a missed dose
A confusing device event does not prove that none, some, or all of the prescribed medicine entered. Repeating an injection could create an unintended extra dose, while assuming complete delivery can also leave the schedule uncertain. The prescriber or pharmacist needs the exact device, official completion checkpoint, scheduled day, event details, symptoms, and other glucose-lowering medicines before deciding what happens next.
- Do not repeat, double, split, retime, redial, or combine injections and do not borrow another person’s pen.
- Do not switch to Mounjaro, a vial, compounded tirzepatide, semaglutide, or another GLP-1 medicine to repair the schedule.
- If the next scheduled dose is approaching before an answer arrives, contact the prescribing team or dispensing pharmacist again rather than applying a generic missed-dose rule.
Product-quality review
Preserve the details needed to assess a possible malfunction
A useful report separates a device defect from package damage, freezing or heat exposure, product appearance, an incompatible or blocked KwikPen needle, presentation mix-up, or unclear training. Keep the carton, pharmacy label, device, lot, expiration date, photos, shipment and storage history, clicks or dose-window observations, visible liquid, and timing when safe. Do not dismantle the device or transfer its contents to investigate it.
- Do not use a pen that is expired, frozen, damaged, cloudy, discolored beyond the labeled appearance, or contains visible particles.
- Contact the prescriber or pharmacist for the treatment decision and Lilly for the branded device problem; replacement or coverage is not guaranteed.
- FDA MedWatch accepts reports about serious adverse events and product-quality problems, but reporting should not delay urgent medical care.
Compounded-product boundary
Zepbound pen instructions do not apply to compounded tirzepatide
Zepbound is an FDA-approved finished branded tirzepatide product. A patient-specific compounded tirzepatide prescription may use a vial or another container, a different concentration, inactive ingredients or additives, separate supplies, pharmacy-specific storage, and a patient-specific label. It is not FDA-approved Zepbound or an FDA-approved generic finished product and does not inherit the Zepbound pen’s clicks, plunger, dose window, manufacturer support, or replacement pathway.
- For a compounded prescription, contact the dispensing pharmacy and prescriber with the exact patient label, concentration, container, supplies, storage history, and event.
- Do not use a branded pen video to estimate syringe units, transfer medicine, reconstitute powder, or create a replacement dose.
- Avoid research-use products, counterfeit pens, unlabeled vials, loose powder, copied dose charts, and sellers that bypass prescription-first clinician review.
Safety escalation
Separate a device question from an urgent medical problem
Most uncertain injections need prompt product-specific advice, but symptoms determine whether waiting for a portal reply is appropriate. Trouble breathing, throat tightness, facial or tongue swelling, fainting, severe confusion, or widespread rapidly worsening hives can require emergency care. Severe or persistent vomiting, inability to keep fluids down, severe abdominal pain, markedly reduced urination, or concerning low-blood-sugar symptoms—especially with insulin or a sulfonylurea—need timely assessment. A needle-stick injury or medicine exposure to the eye also needs immediate first aid and professional guidance.
- Use emergency services for breathing or throat symptoms, facial or tongue swelling, fainting, severe confusion, or a rapidly worsening whole-body reaction.
- Seek timely assessment for severe abdominal pain, repeated vomiting, inability to hydrate, severe weakness, markedly reduced urination, or concerning glucose symptoms.
- Do not delay urgent care while trying to obtain a replacement device, calculate delivery, or complete a product report.